Motion - The available treatments for hepatitis C are cost effective: Arguments against the motion

Canadian Journal of Gastroenterology

Volumn 16, Issue 10, 2002, Pages 710-715

  Kim, W Ray ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cost effectiveness; Hepatitis C

Indexed keywords

ANTIVIRUS AGENT;

AGE; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; NORTH AMERICA; OUTCOMES RESEARCH; PATIENT REFERRAL; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0036812838     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/398016     Document Type: Article

References (26)

1. Gold MR, ed. Cost-effectiveness in Heath and Medicine. New York: Oxford University Press, 1996.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-6.
3. Satcher DA. Letter to Citizen, 2000. http://www.surgeongeneral.gov/topics/hepatitisc/letter.htm.
4. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26(Suppl 1):21S-8S.
5. Seeff LB. The natural history of hepatitis C: A quandary. Hepatology 1998;28:1710-2.
6. Kenny-Walsh E, and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
7. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
8. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000;32:91-6.
9. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
10. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
11. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
12. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. Hepatology 1997;26:485-90.
13. Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study. Hepatology 1997;26:776-9.
14. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6.
15. Anonymous. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
16. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92.
17. Poynard T, Bedossa P, Opolon P, and the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
18. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
19. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-7.
20. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
21. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
22. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-9.
23. Satcher DA. Testimony to Congress Committee on Government Reform and Oversight Subcommittee on Human Resources, 1998.
24. Kim WR, Gross JB Jr, Poterucha JJ, Locke GR III, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001;33:201-6.
25. Koff RS. Therapy of hepatitis C: Cost-effectiveness analysis. Hepatology 1997;26(Suppl 1):152S-5S.
26. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8.